As a result, children with GHD experience psychosocial challenges and poor quality of life, including impaired sleep and difficulty concentrating. "Children have a short time to grow and a lifetime to live, which is why it is so important to help those with GHD have the best chance possible of growing up to achieve normal adult height and experience both good physical and mental health given the substantial psychosocial impact of the disease," said Mary Andrews, Chief Executive Officer and co-founder of the MAGIC Foundation, the global leader in endocrine health, advocacy, education, and support. "Children with GHD and their families have waited years for a long-acting growth hormone therapy that could ultimately reduce the number of injections needed to help these children thrive. We are grateful for Ascendis' commitment to developing this new treatment option for pediatric GHD and making it a reality for patients and their families in the coming years."